>>> Although many here seem to refute it, there is some empirical evidence that FastTrack designation provides for improved share price performance versus peers. <<<
I don't think anyone here denies that stocks usually rise on announcement of FT designation , and I don't recall ever seeing a discussion of the merits of holding companies with FT category approved drugs vs. those with non-FT category drugs.
What has been noted here , correctly I believe , is that FT drug candidates have a lower probability of getting approval than non-FT candidates. They're simply operating in a difficult therapeutic area , which is why they get FT designation in the first place.
So , the strategy would be to sell FT drug companies on the FT announcement , then buy and hold those that end up getting their drug approved.
Market Data 
Markets 
AI
